Introduction Antiretroviral therapy (ART) has transformed prognoses for HIV-1-infected
individuals but requires lifelong adherence to prevent viral resurgence. Targeted elimination …

As increasing numbers of broadly neutralizing monoclonal antibodies (mAbs) against HIV-1
enter clinical trials, it is becoming evident that combinations of mAbs are necessary to block …

Broadly neutralizing antibodies (bNAbs) represent an alternative to drug therapy for the
treatment of HIV-1 infection. Immunotherapy with single bNAbs often leads to emergence of …

ABSTRACT HIV-1 can efficiently replicate by direct transmission from infected to uninfected
CD4+ T cells at confined local sites designated virological synapses (VSs). VSs are formed …

Cross-reactive epitopes (CREs) are similar epitopes on viruses that are recognized or
neutralized by same antibodies. The S protein of SARS-CoV-2, similar to type I fusion …

Summary Soluble HIV-1-envelope (Env) trimers elicit immune responses that target their
solvent-exposed protein bases, the result of removing these trimers from their native …

Background Perinatal human immunodeficiency virus type 1 (HIV-1) continues to occur due
to barriers to effective antiretroviral prevention that might be mitigated by long-acting broadly …

The induction of broadly neutralizing antibodies (bNAbs) is a potential strategy for a vaccine
against HIV-1. However, most bNAbs exhibit features such as unusually high somatic …

Although the efficacy and commercial success of vaccines and therapeutic antibodies have
been tremendous, designing and discovering new drug candidates remains a labor-, time …

Background Although mother-to-child human immunodeficiency virus (HIV) transmission
has dramatically decreased with maternal antiretroviral therapy, breast milk transmission …